임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 16-03-14 02:10
논문번호 152
논문제목(영문) Study design and rationale of
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 공저자
주저자명 Youn YJ
교신저자명 Yoon J
공동저자명 Youn YJ, Lee JW, Ahn SG, Lee SH, Choi HH, Choi H, Choi CU, Lee JB, Cho JH, Kang TS, Cho BR, Cha KS, Kim MH, Hyon MS, Cheong SS, Lim DS, Han KR, Jeong MH, Park KS, Yoon J;
게제년월일 2013-04-29
ISSN 0002-8703
Impact Factor 4.463
학술지명 American heart journal
서지사항 0집 / 166권 / 2호,   페이지(224 - 229)
요약초록문
(Abstract) 입력		 BACKGROUND:
The second-generation drug-eluting stents (DES) have shown superiority in many studies relating to safety and efficacy when compared with the first-generation DES. However, it is unclear whether there are differences in efficacy and safety among the second-generation DES after long-term follow-up.
METHODS:
This multicenter, prospective, randomized, open-labeled trial will directly compare the efficacy and safety among the patients treated with either everolimus-eluting stent (EES), zotarolimus-eluting stent with biolinx polymer (ZES-R), or biolimus-eluting stent (BES) with minimal exclusion criteria. The primary end point is a patient-oriented composite consisted of cardiac death, myocardial infarction not clearly attributable to a nontarget vessel and clinically indicated target lesion revascularization at 24-month clinical follow-up post-index procedure. With the hypothesis that "BES is non-inferior to EES" or "BES is non-inferior to ZES-R" in primary end point, approximately 2,600 patients will be assigned to one of the types of stents using a web-based randomization system.
CONCLUSIONS:
The CHOICE trial will directly compare the efficacy and safety of EES, ZES-R, and BES in everyday clinical practice for long-term follow-up.
파일  C152.+Am+Heart+J.+2013;166(2)224-229. (1).pdf (396.3K) DATE : 2021-05-26 11:29:32